(Q36152764)

12 August 2017

1 reference

title

Menopausal hormone therapy. (English)

1 reference

12 August 2017

Bhagu R Bhavnani

1

1 reference

12 August 2017

Ronald C Strickler

series ordinal

2

1 reference

12 August 2017

publication date

1 February 2005

1 reference

Journal of Obstetrics and Gynaecology Canada

12 August 2017

published in

1 reference

12 August 2017

volume

27

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

137-162

1 reference

Women and the third and fourth age.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Log normal distribution of gonadotropins and ovarian steroid values in the normal menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Steroid and gonadotropin levels in women during the peri-menopausal years

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Postmenopausal hot flushes: a disorder of thermoregulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Experience of menopausal symptoms by Chinese and Canadian women.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen Replacement Therapy II: A Prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic Problems

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Design of the Women’s Health Initiative Clinical Trial and Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effects of estrogen plus progestin on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Lack of sleep disturbance from menopausal hot flashes.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Decision analysis of hormone replacement therapy after the Women's Health Initiative

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hot flashes: epidemiology and physiology

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Comparative study: Replens versus local estrogen in menopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormones and the heart: controversies and conundrums

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The epidemiology of cardiovascular disease in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen and coronary heart disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone replacement therapy, heart disease, and other considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement therapy and prognosis after first myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The protective effects of estrogen on the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The role of hormone replacement therapy in the prevention of postmenopausal heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Possible role of high susceptibility of high-density lipoprotein to lipid peroxidative modification and oxidized high-density lipoprotein in genesis of coronary artery spasm

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement therapy and the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen plus progestin and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A clinical trial of estrogen-replacement therapy after ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS)

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Thrombosis with low-estrogen oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Screening for factor V Leiden mutation before prescribing combination oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

THE METABOLIC EFFECTS OF STEROID HORMONES IN OSTEOPOROSIS.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A review of the prolonged use of estrogens and androgens in postmenopausal and senile osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Breast cancer and hormone-replacement therapy in the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement therapy in breast cancer survivors: a matched-controlled series

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Breast cancer survival and hormone replacement therapy: a cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Strategies to reduce the incidence of endometrial cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Incidence and risk of dementia. The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Development of dementing illnesses in an 80-year-old volunteer cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

An 18-year follow-up of overweight and risk of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Preclinical prediction of Alzheimer's disease using SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

One-year age changes in MRI brain volumes in older adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls).

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Novel mechanisms of estrogen action in the brain: new players in an old story.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Ovarian steroids and the brain: implications for cognition and aging

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen deficiency and risk of Alzheimer's disease in women.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Postmenopausal hormone replacement therapy: scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Hormone replacement therapy and cognition: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The Women’s Health Initiative Memory Study (WHIMS)

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The menopause: sex steroids and osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

The course of adult intellectual development

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2930186-4

7 January 2021

10.1016/S1701-2163(16)30186-4

Identifiers

DOI

1 reference

12 August 2017

1 reference